149 related articles for article (PubMed ID: 26511480)
1. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia.
Park S; Yoon SS; Lee JH; Park JS; Jang JH; Lee JW
Int J Hematol; 2016 Jan; 103(1):44-52. PubMed ID: 26511480
[TBL] [Abstract][Full Text] [Related]
2. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
3. Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.
Newland A; Godeau B; Priego V; Viallard JF; López Fernández MF; Orejudos A; Eisen M
Br J Haematol; 2016 Jan; 172(2):262-73. PubMed ID: 26537623
[TBL] [Abstract][Full Text] [Related]
4. Initial romiplostim dosing and time to platelet response in patients with treatment refractory immune thrombocytopenia.
DasGupta RK; Levine L; Wiczer T; Cataland S
J Oncol Pharm Pract; 2019 Apr; 25(3):567-576. PubMed ID: 29298625
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim for the management of perioperative thrombocytopenia.
Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
[TBL] [Abstract][Full Text] [Related]
6. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis.
Moussa MM; Mowafy N
J Gastroenterol Hepatol; 2013 Feb; 28(2):335-41. PubMed ID: 22849409
[TBL] [Abstract][Full Text] [Related]
7. Romiplostim in the management of the thrombocytopenic surgical patient.
Marshall AL; Goodarzi K; Kuter DJ
Transfusion; 2015 Oct; 55(10):2505-10. PubMed ID: 26033367
[TBL] [Abstract][Full Text] [Related]
8. Romiplostim for secondary thrombocytopenia following allogeneic stem cell transplantation in children.
Maximova N; Zanon D; Rovere F; Maestro A; Schillani G; Paparazzo R
Int J Hematol; 2015 Nov; 102(5):626-32. PubMed ID: 26084627
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia.
Tarantino MD; Bussel JB; Blanchette VS; Beam D; Roy J; Despotovic J; Raj A; Carpenter N; Mehta B; Eisen M
Haematologica; 2019 Nov; 104(11):2283-2291. PubMed ID: 30846500
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes.
Sekeres MA; Kantarjian H; Fenaux P; Becker P; Boruchov A; Guerci-Bresler A; Hu K; Franklin J; Wang YM; Berger D
Cancer; 2011 Mar; 117(5):992-1000. PubMed ID: 20945323
[TBL] [Abstract][Full Text] [Related]
11. Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
Fenaux P; Muus P; Kantarjian H; Lyons RM; Larson RA; Sekeres MA; Becker PS; Orejudos A; Franklin J
Br J Haematol; 2017 Sep; 178(6):906-913. PubMed ID: 28616874
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of self-administered romiplostim in patients with immune thrombocytopenia: Results of an integrated database of five clinical trials.
Kuter DJ; Arnold DM; Rodeghiero F; Janssens A; Selleslag D; Bird R; Newland A; Mayer J; Wang K; Olie R
Am J Hematol; 2020 Jun; 95(6):643-651. PubMed ID: 32129511
[TBL] [Abstract][Full Text] [Related]
13. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
[TBL] [Abstract][Full Text] [Related]
14. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
[TBL] [Abstract][Full Text] [Related]
15. Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim.
Bussel JB; Wang X; Lopez A; Eisen M
Hematology; 2016 May; 21(4):257-62. PubMed ID: 26251926
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
17. A large observational study of patients with primary immune thrombocytopenia receiving romiplostim in European clinical practice.
Steurer M; Quittet P; Papadaki HA; Selleslag D; Viallard JF; Kaiafa G; Janssens A; Kozak T; Wadenvik H; Schoonen M; Belton L; Kreuzbauer G
Eur J Haematol; 2017 Feb; 98(2):112-120. PubMed ID: 27557853
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.
Aoki T; Harada Y; Matsubara E; Suzuki T; Oyama T; Kasai M; Uchida T; Ogura M
J Clin Pharm Ther; 2012 Dec; 37(6):729-32. PubMed ID: 22583038
[TBL] [Abstract][Full Text] [Related]
19. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.
Rodeghiero F; Stasi R; Giagounidis A; Viallard JF; Godeau B; Pabinger I; Cines D; Liebman H; Wang X; Woodard P
Eur J Haematol; 2013 Nov; 91(5):423-36. PubMed ID: 23927437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
